信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002294 信立泰

已收盘 11-26 15:00:00

{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":33.24,"timestamp":1732604598000,"preClose":31.87,"halted":0,"volume":13059956,"delay":0,"floatShares":1115000000,"shares":1115000000,"eps":0.5478,"marketStatus":"已收盘","marketStatusCode":5,"change":1.37,"latestTime":"11-26 15:00:00","open":31.8,"high":34.1,"low":31.8,"amount":437000000,"amplitude":0.0722,"askPrice":33.24,"askSize":19,"bidPrice":33.22,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.5478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732671000000},"adr":0,"adjPreClose":31.87,"symbolType":"stock","openAndCloseTimeList":[[1732584600000,1732591800000],[1732597200000,1732604400000]],"highLimit":35.06,"lowLimit":28.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"pbRate":4.13,"roa":"--","roe":"6.23%","epsLYR":0.52,"committee":0.533333,"marketValue":37057000000,"floatMarketCap":37048000000,"peRate":60.679079,"changeRate":0.043,"turnoverRate":0.0117,"status":0},"requestUrl":"/m/hq/s/002294/tweets","defaultTab":"tweets","newsList":[{"id":"2486777448","title":"11月25日信立泰发生3笔大宗交易 成交金额1335.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486777448","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486777448?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:48","pubTimestamp":1732524488,"startTime":"0","endTime":"0","summary":"证券之星消息，11月25日信立泰发生大宗交易，交易数据如下：近三个月该股共发生4笔大宗交易，合计成交15.42万手，折价成交4笔。该股近期无解禁股上市。截至2024年11月25日收盘，信立泰(002294)报收于31.87元，上涨0.44%，换手率0.64%，成交量7.18万手，成交额2.3亿元。该股最近90天内共有13家机构给出评级，买入评级10家，增持评级3家；过去90天内机构目标均价为39.51。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500021011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0188","BK0183","BK0028","BK0196","BK0187"],"gpt_icon":0},{"id":"2485237897","title":"信立泰(002294.SZ)拟3000万元增资普瑞基准 提升研发效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2485237897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485237897?lang=zh_cn&edition=full","pubTime":"2024-11-22 18:03","pubTimestamp":1732269817,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 公告，公司拟以自筹资金人民币3000万元增资参股公司普瑞基准科技(北京)有限公司，获得普瑞基准3.2154%股权。本次增资完成后，公司将直接持有普瑞基准8.5745%股权。公告显示，普瑞基准是一家为新药研发企业提供基于多组学数据挖掘的研发决策支持、中心实验室检测服务、转化医学服务公司，在多组学技术、生物信息学、生物统计/机器学习、中心实验室服务和伴随诊断开发方面具备独特技术。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294","BK0187","BK0196","BK0183","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2485467455","title":"信立泰：仿制药龙头押注创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485467455","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485467455?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:37","pubTimestamp":1732189020,"startTime":"0","endTime":"0","summary":"多款创新产品上市信立泰营收过去主要依赖仿制药，但公司多年来积极布局创新转型，研发投入不断加大，同时重视研发团队建设。其中，苯甲酸福格列汀片和阿利沙坦酯氨氯地平片，分别是1类新药、2类新药，表明信立泰创新转型产出重要成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2024-11-21/doc-incwvpzh4575306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK1574","BK0239","BK1161","BK0187","BK0188","002294","BK0183","06978","BK0196","159992"],"gpt_icon":0},{"id":"2484840521","title":"信立泰（002294）11月19日主力资金净卖出2318.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484840521","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484840521?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:21","pubTimestamp":1732065708,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月19日收盘，信立泰报收于30.18元，下跌0.63%，换手率0.95%，成交量10.53万手，成交额3.16亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入3176.96万元，融资偿还1362.11万元，融资净买入1814.85万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000009724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","002294","BK0239","BK0187","BK0188","BK0028"],"gpt_icon":0},{"id":"2481693369","title":"信立泰（002294）11月5日主力资金净卖出1317.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481693369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481693369?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:19","pubTimestamp":1730855988,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月5日收盘，信立泰报收于32.82元，下跌1.44%，换手率0.84%，成交量9.37万手，成交额3.09亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入3844.99万元，融资偿还2771.62万元，融资净买入1073.37万元。融券方面，融券卖出0.0股，融券偿还2.27万股，融券余量7.47万股，融券余额245.17万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600009061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0187","BK0239","BK0028","002294","BK0196"],"gpt_icon":0},{"id":"2479279874","title":"信立泰：10月29日接受机构调研，交银基金、国泰君安等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479279874?lang=zh_cn&edition=full","pubTime":"2024-10-30 18:06","pubTimestamp":1730282778,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月30日信立泰发布公告称公司于2024年10月29日接受机构调研，交银基金徐嘉辰、国泰君安付子阳、东吴证券张坤 张翀翯 朱俊佳、富国基金王超 赵伟 曾新杰 孙笑悦 杨波参与。S086未来的市场竞争格局良好，获批后我们将争取医保准入。答：0108已申报上市，并提交发补，预计25年初获批。该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为37.18。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000035852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0028","BK0276","BK0188","BK1564","601211","02611","BK1147","BK0184","BK0196","BK0012","BK0239","002294","BK0201"],"gpt_icon":0},{"id":"2477524821","title":"华安证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477524821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477524821?lang=zh_cn&edition=full","pubTime":"2024-10-24 13:45","pubTimestamp":1729748719,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对信立泰进行研究并发布了研究报告《24Q3营收扣非超预期，恩那罗未来可期》，本报告对信立泰给出买入评级，当前股价为32.95元。我们看好公司创新转型带来的收入结构重塑，在心血管专科领域的深耕优势，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为37.18。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400018214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","002294"],"gpt_icon":0},{"id":"2477511457","title":"信立泰（002294）10月23日主力资金净卖出1503.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477511457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477511457?lang=zh_cn&edition=full","pubTime":"2024-10-24 09:21","pubTimestamp":1729732918,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月23日收盘，信立泰报收于33.31元，下跌3.73%，换手率1.19%，成交量13.21万手，成交额4.44亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入5689.79万元，融资偿还3282.38万元，融资净买入2407.42万元，连续3日净买入累计7038.29万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400008311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0196","BK0239","BK0028","BK0188","002294","BK0187"],"gpt_icon":0},{"id":"2477324325","title":"华鑫证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477324325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477324325?lang=zh_cn&edition=full","pubTime":"2024-10-23 13:40","pubTimestamp":1729662029,"startTime":"0","endTime":"0","summary":"华鑫证券胡博新近期对信立泰进行研究并发布了研究报告《公司事件点评报告：持续加码研发，重磅品种稳步推进》，本报告对信立泰给出买入评级，当前股价为33.46元。创新药产品线持续丰富，收入占比稳步提升。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为37.18。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300018552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","161027"],"gpt_icon":0},{"id":"2477924183","title":"信立泰（002294）2024年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2477924183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477924183?lang=zh_cn&edition=full","pubTime":"2024-10-23 06:04","pubTimestamp":1729634677,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期信立泰发布2024年三季报。根据财报显示，信立泰营收净利润同比双双增长。截至本报告期末，公司营业总收入30.01亿元，同比上升22.18%，归母净利润5.1亿元，同比上升6.37%。按单季度数据看，第三季度营业总收入9.58亿元，同比上升24.15%，第三季度归母净利润1.66亿元，同比上升17.01%。持有信立泰最多的基金为工银前沿医疗股票A，目前规模为97.86亿元，最新净值2.811，较上一交易日上涨0.32%，近一年下跌6.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300004659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2477238808","title":"信立泰（002294）10月21日主力资金净卖出800.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477238808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477238808?lang=zh_cn&edition=full","pubTime":"2024-10-22 09:23","pubTimestamp":1729560232,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月21日收盘，信立泰报收于36.31元，下跌1.28%，换手率0.77%，成交量8.55万手，成交额3.09亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入3000.13万元，融资偿还1351.49万元，融资净买入1648.64万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200007462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0187","BK0183","BK0188","BK0239","002294"],"gpt_icon":0},{"id":"2477899507","title":"图解信立泰三季报：第三季度单季净利润同比增17.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477899507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477899507?lang=zh_cn&edition=full","pubTime":"2024-10-22 00:33","pubTimestamp":1729528439,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰2024年三季报显示，公司主营收入30.01亿元，同比上升22.18%；归母净利润5.1亿元，同比上升6.37%；扣非净利润4.97亿元，同比上升14.94%；其中2024年第三季度，公司单季度主营收入9.58亿元，同比上升24.15%；单季度归母净利润1.66亿元，同比上升17.01%；单季度扣非净利润1.64亿元，同比上升30.87%；负债率15.52%，投资收益1204.53万元，财务费用-2290.16万元，毛利率72.07%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200000158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2477865781","title":"信立泰前三季度净利约5.1亿元，同比增加6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477865781","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477865781?lang=zh_cn&edition=full","pubTime":"2024-10-21 21:15","pubTimestamp":1729516500,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 丁宁）10月21日晚间，信立泰（002294）发布三季报显示，公司前三季度实现营业收入约30.01亿元，同比增加22.18%；对应实现的归属净利润约5.1亿元，同比增加6.37%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-21/doc-inctiptv9152306.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-21/doc-inctiptv9152306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","BK0196","BK0239","BK0028","BK0188","002294","BK0187"],"gpt_icon":0},{"id":"2477855987","title":"信立泰(002294.SZ)发布前三季度业绩，净利润5.1亿元，同比增长6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477855987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477855987?lang=zh_cn&edition=full","pubTime":"2024-10-21 19:14","pubTimestamp":1729509287,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布2024年第三季度报告，公司前三季度营业收入30.01亿元，同比增长22.18%;归属于上市公司股东的净利润5.1亿元，同比增长6.37%;归属于上市公司股东的扣除非经常性损益的净利润4.97亿元，同比增长14.94%;基本每股收益0.46元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1196966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294"],"gpt_icon":0},{"id":"2477553958","title":"信立泰(002294.SZ)拟斥5000万美元向子公司Salubris Bio增资 加快生物药海外研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2477553958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477553958?lang=zh_cn&edition=full","pubTime":"2024-10-21 19:11","pubTimestamp":1729509078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 公告，Salubris Biotherapeutics, Inc.为公司位于美国的创新生物制药研发中心，由公司通过全资子公司诺泰国际有限公司等公司实现逐级控股。为进一步支持创新生物制药发展，加快生物药海外研发进程，公司拟以自筹资金5000万美元向Salubris Bio增资。增资完成后，公司对Salubris Bio的投资总额将由人民币97,154.32万元增至人民币132,191.32万元，Salubris Bio仍为公司控股子公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1196960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0187","159839","BK0239","BK0183","BK0028","002294","BK0188"],"gpt_icon":0},{"id":"2477587348","title":"信立泰最新公告：前三季度实现净利润5.1亿元 同比增长6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477587348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477587348?lang=zh_cn&edition=full","pubTime":"2024-10-21 18:50","pubTimestamp":1729507801,"startTime":"0","endTime":"0","summary":"信立泰发布2024年第三季度报告，前三季度实现营业收入30.01亿元，同比增长22.18%；实现净利润5.1亿元，同比增长6.37%；基本每股收益0.46元。公司表示，随着创新产品和信立泰品牌被医生、患者的认同、接受度越来越高，加上产品线的不断丰富，创新产品的收入及利润贡献占比持续提升，实现了收入和利润较好的增长。同时，公司加大了产品推广和创新研发的投入。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102100024598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2477858423","title":"信立泰最新公告：拟3.5亿元增资控股子公司Salubris Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2477858423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477858423?lang=zh_cn&edition=full","pubTime":"2024-10-21 18:49","pubTimestamp":1729507781,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司拟以自筹资金5,000万美元（约合人民币3.5亿元）向其位于美国的创新生物制药研发中心Salubris Bio增资。增资完成后，公司对Salubris Bio的投资总额将增至约人民币13.22亿元，Salubris Bio仍为公司控股子公司。增资款计划主要投向JK07、JK06的临床研究，以及Salubris Bio平台建设和研发管线的布局等。本次增资符合子公司业务发展的实际需要，符合公司发展战略和长远规划。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102100024599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","002294","BK0239","BK0188","BK0028","BK0183","BK0196"],"gpt_icon":0},{"id":"2475272593","title":"信立泰（002294）10月14日主力资金净卖出1703.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475272593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475272593?lang=zh_cn&edition=full","pubTime":"2024-10-15 09:23","pubTimestamp":1728955423,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月14日收盘，信立泰报收于34.78元，下跌0.23%，换手率0.75%，成交量8.38万手，成交额2.88亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1717.55万元，融资偿还2532.78万元，融资净偿还815.23万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500007761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","002294","BK0183","BK0188","BK0196","BK0239","BK0028"],"gpt_icon":0},{"id":"2474574643","title":"信立泰（002294）股东信立泰药业有限公司质押2100万股，占总股本1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474574643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474574643?lang=zh_cn&edition=full","pubTime":"2024-10-10 21:28","pubTimestamp":1728566905,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰10月10日公开信息显示，股东信立泰药业有限公司向集友银行有限公司合计质押2100.0万股，占总股本1.88%。质押详情见下表：截止本公告日，股东信立泰药业有限公司已累计质押股份1.64亿股，占其持股总数的25.86%。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000038444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0028","002294","BK0187","BK0239","BK0183"],"gpt_icon":0},{"id":"2471670818","title":"信立泰（002294）9月27日主力资金净买入1864.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471670818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471670818?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:23","pubTimestamp":1727659438,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月27日收盘，信立泰报收于32.12元，上涨2.13%，换手率0.8%，成交量8.92万手，成交额2.86亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入3672.49万元，融资偿还3350.54万元，融资净买入321.95万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000006384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK0188","BK0239","BK0183","BK0187","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","stockEarnings":[{"period":"1week","weight":0.1014},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.111},{"period":"6month","weight":0.2587},{"period":"1year","weight":0.0303},{"period":"ytd","weight":0.0363}],"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","perCapita":"42661股","boardName":"医药制造业","registeredCapital":"111481万元","compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0121},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.0544},{"period":"1year","weight":0.0752},{"period":"ytd","weight":0.0957}],"survey":"　　深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。","serverTime":1732666810022,"listedPrice":41.98,"stockholders":"26126人(较上一季度减少7.20%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}